Organon

Jersey City, United States Listed Acquired By Sun Pharma
Organon is focused on improving womens health globally.

About Organon

Organon is a publicly listed company based in Jersey City (United States), and was acquired by Sun Pharma in April 2026. Organon is focused on improving womens health globally. It operates on a Direct-to-Consumer (D2C) and Professional Services model. Organon has completed 4 acquisitions, including Alydia Health, Dermavant and Forendo Pharma. Organon offers products and services including Women's Health Solutions, Biosimilars, and Established Brands. Its focus areas include Pharmaceuticals, Women's Health, Biotechnology and Biosimilars. Its legal entity is Organon Denmark ApS. Its competitors include Roivant Sciences, Gilead and Lilly; 1 of its 3 listed competitors has raised funding.

Company details

Organon is dedicated to advancing womens health through a diverse portfolio of over 70 medicines and devices. Focus areas include reproductive health, maternal conditions, and contraception, alongside biosimilars and established brands in cardiovascular, neurology, and dermatology sectors. Therapies are delivered to over 140 markets worldwide, addressing conditions unique to women or affecting them disproportionately. Solutions are developed to support women at all life stages, ensuring accessible healthcare options for patients and providers.

  • Headquarters Jersey City, United States
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website organon.com
  • Social LinkedIn X Facebook Instagram YouTube
  • Acquired by Merck (Nov 2007)
  • Legal Name Organon & Co.
Key Metrics
  • Annual Revenue
    $6.22 B (USD)
    -2.92
    as on Dec 31, 2025
  • Net Profit
    $187 M (USD)
    -78.36
    as on Dec 31, 2025
  • EBITDA
    $1.64 B (USD)
    -7.83
    as on Dec 31, 2025
  • Investors
    Merck

    & 1 more

  • Investments & Acquisitions
  • Acquired by
    Sun Pharma

    & 1 more

    (Apr 2026)

Products & Services of Organon

Organon offers a comprehensive portfolio of products and services, including Women's Health Solutions, Biosimilars, and Established Brands.

Women's Health Solutions
Healthcare

Solutions for women's reproductive and maternal health are provided.

Biosimilars
Healthcare

Accessible treatment options through biosimilars are made available.

Established Brands
Healthcare

Therapies for various conditions like cardiovascular are offered.

Apps and channels of Organon

its YouTube channel Organon has 476 subscribers and 30 videos.

Organon
YouTube 476 subscribers 30 videos Howto & Style
Open channel

Videos from Organon

The most watched videos on Organon's YouTube channel, Organon (476 subscribers). Click a video to play it here.

Things You Didn't Know About Organon
324 views
Minds Behind the Science featuring Rania Haggag
187 views
Minds Behind the Science featuring Jasmin Tiala
159 views
Mis[s]Diagnosed Addresses the Medical Gender Data Gap in Cardiovascular Health
124 views

More on Organon.

Investors in Organon

Organon has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Merck and Sun Pharma.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Pharmaceutical products are manufactured and marketed worldwide.
1891merck.comKenilworth, United Kingdom
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983sunpharma.comMumbai, India
Premium access

Investor details for Organon

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Organon

337 people are tracked at Organon (206 in leadership, 10 in board & advisors, 121 in team).

NameRoleGroup
Damien Morris
Associate Director Of Finance External ManufacturingLeadership
Charlotte Owens
Head of Medical Affairs & Outcomes ResearchLeadership
Sara Dean
Global Director, Medical Affairs - Contraception StrategyLeadership
Mostafa Taha
Global Director Commercial Trade ChannelsLeadership
Eddie Yu
Director, Finance - Above Market AccountingLeadership
Leanne Miller
Associate Director, Customer Experience & Commercial AccelerationLeadership
Sadia Khan
Director Fp&a And StrategyLeadership
Nadim Hawwari
SCM & Integration Finance Associate DirectorLeadership
Therry Engelen
Associate Director / Operations LeadLeadership
Wayne Chen
Executive Director, Translational Medicine And Early Clinical Development LeadLeadership
Julie Pentz
Chief Procurement OfficerLeadership
Rijesh Shrestha
Director, Transfer PricingLeadership
Glenn Coleman
Associate Director, Business Technology Processes & GovernanceLeadership
Rachel Stahler
Chief Digital & Growth OfficerLeadership
Subhajit Singha
Associate Director - Enterprise Data & Analytics PlatformLeadership
Sloan Tandet
Associate Director, Market Research Global Commercial Insights & AnalyticsLeadership
Samantha Bruno
DirectorLeadership
Wendy Wocher
Associate Director Business/tech. AnalysisLeadership
Julia Luftmann
Associate Director, Compliance & Operations - Global Business Insights And AnalyticsLeadership
Lauren Caruso Davis
Associate Director Brand AnalyticsLeadership

317 more people are available in the full profile.

Premium access

Complete people profiles for Organon

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Organon

Organon is a publicly listed company on the NYSE with ticker symbol OGN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date14 May 2021
  • Listed onNYSE: OGN
  • Listed entityOrganon & Co.
  • Exchange sectorHealth technology
  • ISINUS68622V1061
  • Share price$13.77 · 2026-10-13
  • Market capitalisation$3.62B
  • Price to earnings17.6
  • EPS (diluted, trailing year)$0.78
  • Dividend yield0.58%
  • Volume (last session)2,893,105

Financials of Organon

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$6.22B$187.0M$1.64B
2024$6.40B$864.0M$1.77B
2023$6.26B$1.02B$1.56B
2022$6.17B$917.0M$1.93B
2021$6.36B$1.35B$2.07B
Premium access

Detailed financial statements for Organon

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Organon

Organon has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Alydia Health, Dermavant and Forendo Pharma.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Small molecule therapeutics for inflammatory skin diseases are developed.
dermavant.comPhoenix, United States2016Sep 2024$1.2B
Small molecule therapeutics for reproductive health are developed.
forendo.comTurku, Finland2013Nov 2021$75M
Medical devices for postpartum hemorrhage treatment are developed.
alydiahealth.comMenlo Park, United States2010Mar 2021$215M
Postpartum hemorrhage is controlled via vacuum-induced uterine contraction devices.
thejadasystem.comSan Mateo, United States2020Mar 2021$240M
Premium access

Complete acquisition details for Organon

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Organon

7 dated milestones of Organon across 19 years, from founding to its latest funding, stage changes and deals.

  1. Exit Acquired by Merck.
  2. Acquisition Acquires The JADA System.
  3. Acquisition Acquires Alydia Health.
  4. IPO Lists on the stock exchange (IPO).
  5. Acquisition Acquires Forendo Pharma.
  6. Acquisition Acquires Dermavant.
  7. Exit Acquired by Sun Pharma.

Competitors of Organon

Organon has 3 listed competitors in our database, 1 of them funded. They include Roivant Sciences, Gilead and Lilly.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
roivant.com2014New York, United States$1.3B662
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
gilead.com1987Foster, United States4,267
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
lilly.com1876United States39,000
Traditional pharmaceutical medicines are developed for multiple health fields.
Premium access

Detailed competitors of Organon

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Organon

Websites that share an audience with Organon (organon.com).

Similar websites

Websites whose visitors overlap most with Organon. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
bauschhealth.com
100%
32.2K#988,502View details
henlius.com
95%
25K#1,127,187View details
formatech.com
91%
View details
stridesarco.com
90%
View details
mn.com.tr
82%
View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 10 similar websites and full traffic analytics for Organon

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 10 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Women's Health & Fertility

3 companies that operate in the same segment as Organon (Women's Health & Fertility) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of cell-free DNA testing for oncology, women’s health, and organ health
2004Redwood City, California, United StatesUSD 152.1 MUSD 2.31 B4,430
Therapeutics for women's healthcare are developed and offered.
1997Princeton, New Jersey, United StatesUSD 123.06 MUSD 19.59 M
Provider of cell-free cancer liquid biopsy test
2015San Francisco, California, United StatesUSD 388.62 M861
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Organon

Premium access

Complete news archive for Organon

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Organon

Organon is headquartered in Jersey City, United States. It is registered at Jersey City, New Jersey, United States.

Annual revenue of Organon is $6.22B as on Dec 31, 2025.

Organon is dedicated to advancing womens health through a diverse portfolio of over 70 medicines and devices. Focus areas include reproductive health, maternal conditions, and contraception, alongside biosimilars and established brands in cardiovascular, neurology, and dermatology sectors. Therapies are delivered to over 140 markets worldwide, addressing conditions unique to women or affecting them disproportionately. Solutions are developed to support women at all life stages, ensuring accessible healthcare options for patients and providers.

Organon's top competitors include Roivant Sciences, Lilly and Gilead.

Organon offers Women's Health Solutions, Biosimilars, and Established Brands.

Yes, Organon is publicly traded on NYSE under the ticker symbol OGN.

Organon has made 4 acquisitions, including Alydia Health, Dermavant, and Forendo Pharma.

Organon has 2 investors. Key investors include Merck, and Sun Pharma.

Organon operates through Organon Denmark Aps.

Yes. Organon was acquired by Merck in November 2007.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available